- Home
- IMCR vs PARR Comparison
IMCR vs PARR Comparison
Compare IMCR & PARR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- PARR
- Stock Information
- Founded
- IMCR 2008
- PARR 1984
- Country
- IMCR United Kingdom
- PARR United States
- Employees
- IMCR N/A
- PARR N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- PARR Integrated oil Companies
- Sector
- IMCR Health Care
- PARR Energy
- Exchange
- IMCR Nasdaq
- PARR Nasdaq
- Market Cap
- IMCR 1.8B
- PARR 1.5B
- IPO Year
- IMCR 2021
- PARR N/A
- Fundamental
- Price
- IMCR $37.20
- PARR $33.87
- Analyst Decision
- IMCR Buy
- PARR Hold
- Analyst Count
- IMCR 9
- PARR 6
- Target Price
- IMCR $57.00
- PARR $25.79
- AVG Volume (30 Days)
- IMCR 284.7K
- PARR 1.6M
- Earning Date
- IMCR 11-05-2025
- PARR 11-03-2025
- Dividend Yield
- IMCR N/A
- PARR N/A
- EPS Growth
- IMCR N/A
- PARR N/A
- EPS
- IMCR N/A
- PARR N/A
- Revenue
- IMCR $356,145,000.00
- PARR $7,614,628,000.00
- Revenue This Year
- IMCR $31.83
- PARR N/A
- Revenue Next Year
- IMCR $8.50
- PARR N/A
- P/E Ratio
- IMCR N/A
- PARR N/A
- Revenue Growth
- IMCR 26.78
- PARR N/A
- 52 Week Low
- IMCR $23.15
- PARR $11.86
- 52 Week High
- IMCR $39.33
- PARR $35.94
- Technical
- Relative Strength Index (RSI)
- IMCR 76.55
- PARR 59.73
- Support Level
- IMCR $31.85
- PARR $33.38
- Resistance Level
- IMCR $33.08
- PARR $35.94
- Average True Range (ATR)
- IMCR 1.28
- PARR 1.63
- MACD
- IMCR 0.50
- PARR 0.33
- Stochastic Oscillator
- IMCR 100.00
- PARR 74.44
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About PARR Par Pacific Holdings Inc.
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments namely Refining, Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operation licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.